OncoMatch/Clinical Trials/NCT02443831
CARPALL: Immunotherapy with CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
Is NCT02443831 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including CD19+CD22 CAR T-cells and Lymphodepletion with Fludarabine for acute lymphoblastic leukemia.
Treatment: Lymphodepletion with Fludarabine · Lymphodepletion with Cyclophosphamide · CD19+CD22 CAR T-cells — This study aims to evaluate the safety, efficacy and duration of response of CD19+CD22 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in children with high risk, relapsed CD19+ and CD22+ acute lymphoblastic leukaemia
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 overexpression (positive)
CD19+ acute lymphoblastic leukaemia
Required: CD22 overexpression (positive)
CD22+ acute lymphoblastic leukaemia
Allowed: KMT2A (MLL) rearrangement
MLL gene rearrangement
Allowed: TCF3 HLF rearrangement
t(17,19) TCF3-HLF rearrangement
Allowed: TCF3 PBX1 rearrangement
t(1;19)(q21;p13)/TCF3-PBX1
Allowed: BCR ABL1 rearrangement
t(9;22)(34.1 q11.2)/BCR-ABL1
Demographics
Lab requirements
Kidney function
creatinine > 3 x upper limit of normal
Liver function
bilirubin > 3 x upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT02443831 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require CD19?
Yes, CD19 overexpression is a required biomarker for enrollment.
Does this trial require CD22?
Yes, CD22 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 24 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages